PRA Opens Office in Romania
PRA recently opened a new office in Bucharest, Romania to further strengthen its coverage of the Balkan region’s burgeoning markets. The Bucharest office will also support projects in the neighboring Republic of Moldova.
Since 2006, when PRA began conducting clinical trials in Romania, the PRA staff has steadily increased and now includes both product registration and early phase professionals. The number of studies initiated by PRA in this region has more than doubled over the last two years.
“By being based in the Balkan region’s key business and life sciences hub, the Bucharest staff has convenient access to top universities, academic research sites, and most of the country’s major hospitals,” said Ludger Langer, PRA’s Vice President of Clinical Operations in Europe, Asia-Pacific and Africa.
The Bucharest location is the 12th office PRA has opened worldwide since 2009, demonstrating its commitment to meeting its clients’ diverse needs in a dynamic clinical trials environment.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
